Cellid, Co., Ltd.
Financials
Valuation Metrics
Cellid, Co., Ltd.'s Market Cap is ₩547B. At end of 2025 it was ₩844B. Ranked #1648 of 2,405 in KR market (top 69%), #983 of 1,627 on KOSDAQ (top 60%), #179 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 77%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 54.70B KRW | KR#1,648/2,405 Sec#179/231 |
| Revenue | 10.42B KRW | KR#2,276/2,405 Sec#177/231 |
| Net Income | -27.38B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 96.83B KRW | KR#1,810/2,405 Sec#143/231 |
| Net Assets | 53.67B KRW | KR#1,858/2,405 Sec#158/231 |
| Employees | 56 | KR#1,995/2,405 Sec#180/231 |
| Value | ||
| P/B | 1.02x | KR#1,549/2,405 Sec#97/231 |
| P/S | 5.25x | KR#2,170/2,405 Sec#148/231 |
| FCF Yield | -42.10% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -51.02% | KR#2,264/2,405 Sec#197/231 |
| ROA | -28.28% | KR#2,292/2,405 Sec#197/231 |
| Op. Margin | -99.30% | KR#2,284/2,405 Sec#173/231 |
| Revenue Growth | 49.87% | KR#210/2,405 Sec#30/231 |
| Financial Health | ||
| Debt Ratio | 80.41% | KR#1,347/2,405 Sec#158/231 |
| Total Debt | 33.63B KRW | KR#1,168/2,405 Sec#84/231 |
| FCF | -23.03B KRW | KR#1,917/2,405 Sec#185/231 |
| Cash | 12.98B KRW | KR#1,538/2,405 Sec#125/231 |
| Current Ratio | 0.57x | KR#2,083/2,405 Sec#199/231 |
| Performance | ||
| 1Y Return | -44.63% | KR#1,808/2,405 Sec#154/231 |
| 1M Return | -24.13% | KR#2,058/2,405 Sec#202/231 |
| From 52W High | -61.03% | KR#1,707/2,405 Sec#142/231 |
| 1Y MDD | -75.06% | KR#2,142/2,405 Sec#187/231 |
| Trading | ||
| Volume | 175,383 shares | KR#424/2,405 Sec#44/231 |
| Trading Value | 325.8M KRW | KR#953/2,405 Sec#110/231 |
| Foreign Own. | 0.90% | KR#2,061/2,405 Sec#202/231 |
| Per Share | ||
| EPS | -928 KRW | KR—/2,405 Sec—/231 |
| BPS | 1,819 KRW | KR#2,109/2,405 Sec#175/231 |
Company Info
Cellid, a bio-venture established in 2006, expanded its business in 2024 by merging with ForBaker Co., Ltd. to establish an e-commerce division. The company develops CeliVax-based anti-cancer immunotherapy vaccines and adenovirus vector-based COVID-19 prophylactic vaccines, while also operating biopharmaceutical contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) services from its 2020 GMP facility. Its anti-cancer immunotherapy vaccines are undergoing clinical and non-clinical trials, and its Omicron-specific COVID-19 vaccine has completed Phase 3 administration. Cellid is headquartered in Gwanak-gu, Seoul.